Open AccessWhat is the appropriate duration of adjuvant imatinib mesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture?
Author(s) -
Jun Lü,
Yun Dai,
HuaLong Zheng,
JianWei Xie,
Jia-Bin Wang,
Lin Ji,
QiYue Chen,
LongLong Cao,
Lin Ma,
RuHong Tu,
ZeNing Huang,
JuLi Lin,
Ping Li,
ChangMing Huang,
Chao-Hui Zheng
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000014177
Subject(s) - medicine , gist , stromal tumor , imatinib mesylate , primary tumor , adjuvant therapy , imatinib , oncology , adjuvant , surgery , stromal cell , cancer , metastasis , myeloid leukemia
Supplemental Digital Content is available in the text